Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E K Rowinsky

Showing results (91-100 of 159) with videos related to

Pageof 16
Sort By:
Anti-Cancer Drugs|December 10, 1999
Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming unitsM Hidalgo, E Izbicka, S G Eckhardt, et al.
Cancer Research|January 15, 1994
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeksE K Rowinsky, L B Grochow, D S Ettinger, et al.
Cancer Chemotherapy and Pharmacology|July 21, 1999
Activity of the multitargeted antifolate LY231514 in the human tumor cloning assayC D Britten, E Izbicka, S Hilsenbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1993
Successful re-treatment with taxol after major hypersensitivity reactionsD M Peereboom, R C Donehower, E A Eisenhauer, et al.
Anti-Cancer Drugs|October 3, 1999
Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cellsR A Lawrence, E Izbicka, R L De Jager, et al.
Journal of the National Cancer Institute|January 18, 1989
Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamicsL B Grochow, D A Noe, G B Dole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Phase I and pharmacologic study of topotecan in patients with impaired renal functionS O'Reilly, E K Rowinsky, W Slichenmyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignanciesG Schwartz, T R Johnson, A Goetz, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2000
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft modelL A Hammond, S G Hilsenbeck, S G Eckhardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and IIA A Adjei, M Charron, E K Rowinsky, et al.
Pageof 16

Showing results (91-100 of 159) with videos related to

Sort By:
Pageof 16
Anti-Cancer Drugs|December 10, 1999
Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming unitsM Hidalgo, E Izbicka, S G Eckhardt, et al.
Cancer Research|January 15, 1994
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeksE K Rowinsky, L B Grochow, D S Ettinger, et al.
Cancer Chemotherapy and Pharmacology|July 21, 1999
Activity of the multitargeted antifolate LY231514 in the human tumor cloning assayC D Britten, E Izbicka, S Hilsenbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1993
Successful re-treatment with taxol after major hypersensitivity reactionsD M Peereboom, R C Donehower, E A Eisenhauer, et al.
Anti-Cancer Drugs|October 3, 1999
Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cellsR A Lawrence, E Izbicka, R L De Jager, et al.
Journal of the National Cancer Institute|January 18, 1989
Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamicsL B Grochow, D A Noe, G B Dole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Phase I and pharmacologic study of topotecan in patients with impaired renal functionS O'Reilly, E K Rowinsky, W Slichenmyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignanciesG Schwartz, T R Johnson, A Goetz, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2000
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft modelL A Hammond, S G Hilsenbeck, S G Eckhardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and IIA A Adjei, M Charron, E K Rowinsky, et al.
Pageof 16